New proton beam method targets tough sarcoma tumors

NCT ID NCT06327477

Recruiting now Disease control Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This early-phase trial tests a new type of proton radiation called P-SFRT, which delivers high doses to tumors while sparing nearby organs. It is for people with newly diagnosed retroperitoneal soft tissue sarcoma that has not been treated yet. The study aims to find the best dose and see if combining it with standard radiation improves tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Proton-spatially fractionated radiotherapy (P-SFRT)
What this could lead to: If successful, this could offer a more effective radiation approach for a hard-to-treat sarcoma, potentially improving tumor shrinkage and local control.
What could go wrong: This is an early first-in-human trial with only 28 participants, so safety and efficacy are not yet established. There is a risk of side effects from high-dose radiation near sensitive organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETROPERITONEAL SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retroperitoneal sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RETROPERITONEAL SARCOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Northwestern University
RECRUITING

Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.